Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients

Summary

• Vera Therapeutics, Inc. topline 36-week data from the phase 3 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected Q2 of 2025.
• 96-week data from the phase 2 ORIGIN study, using Atacicept for the treatment of patients with IgA Nephropathy, expected at ASN Kidney week oral presentation October 23–27 2024.
• The global IgA Nephropathy market is expected to reach $41.24 billion by 2033.
• Possible expansion opportunities would include targeting other IgAN subpopulations like anti-PLA2R and anti-nephrin podocytopathies; Along with using the drug for rheumatological and hematological indications.
• Looking for more investing ideas like this one? Get them exclusively at Biotech Analysis Central. Learn More »

SolStock

Vera Therapeutics, Inc. (NASDAQ:VERA) is gearing up to report 96-week long-term results from its phase 2b ORIGIN study using its drug Atacicept for the treatment of patients with IgA nephropathy [IgAN]. This set of data from this particular

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.